Consultants in Drug and Biologics Development. Focused areas of interest: Applied Imaging Technologies, Pharmacokinetics, Radiobiology, Physical Toxicology (radiation, microwaves, energy exposures), Biodosimetry, Model Systems Development, and RegulatoryApproaches
A New Hampshire-based organization, our team has over 150 years in combined experience in developing nuclear medicine and MR contrast agent products and experience in developing medical countermeasures for pathologies related to radiation and chemical injury. We have a wide background in the control of such exposures includes instrumentation, dermal, inhalation, and oral routes. Radiation exposure dosimetry, sources, and assessments of internal contamination are from year of academic and biotechnology industry research.
Our Goals are Your Goals: We can aid in your quest for animal models of disease, toxicology and efficacy studies, analytical testing processes, statistical assessments, PK/PD/TK analyses, process development and manufacturing, pre-clinical and clinical protocol designs, subcontractor site visits and FDA submissions:
Our diverse backgrounds and broad industry contacts allows us to bring the expertise that is needed to specific problem solving opportunities in the diverse biotechnology fields.
Mr Moyer's Expertise: Mr Moyer is currently a Sr Scientific Advisor for CBRN medical countermeasures and radiation dosimetry in mass casualty chemical and radiation events (IND, RDD and RED) for BARDA (HHS/ASPR, US Gov; Biomedical Advanced Research and Development Authority, Washington, DC; retired from full time contractor activities in July 2016 and brought back in July 2017). Mr Moyer has also been conferred Emeritus status by the Nuclear Medicine Technology Certification Board in 2017.
He is a Clinical Pharmacologist who has specialized in the development and clinical uses for imaging agents in both nuclear (PET/SPECT) and MRI (Gd, Mn and Dy). A specialist in PK/PD analysis and models of disease he has worked in the fields of infection/sepsis, vascular, hematopoietic, neurologic, gastrointestinal, renal, hepatic, pulmonary, and bone pain. Significant participation in the approvals of 8 drug NDAs and 3 BLAs and other product experience with Mabs, Nabs, cell therapies, recombinant proteins, peptides and glycan drug development.
Consultant services options: Mr. Moyer has been contracted by HHS/BARDA for a term of one year as a Special Government Employee/ Consultant/ SME for the radiation medical countermeasures group which prohibits his participation as a consult or to work on projects for or involving BARDA or the US Government. This work assignment will preclude any medical countermeasure development work related to the BARDA portfolio (www.phe.gov) until his service period has ended. All other development work where we may be able to assist you, is welcomed.
See below for a link to his contributed chapters in an upcoming Wiley Book on "Imaging and Quantitative Systems Pharmacology" which is scheduled for release in early 2021
Please contact us using our Contact Page if you have any questions or request for services.
Mr Moyer is the former Chair of the AAPS Pharmaco-Imaging Focus Group (2013-14) and serves as the Editor of the PIFG Newsletter.